Cardiovascular Genomic Diagnostics Market Segmented By Test Type such as Predictive Testing, Carrier Screening, Prenatal Testing, Genotyping with Disease indication such as Congenital Heart Disease, Cardiac Channelopathies, Familial Hyper-Cholestrolaemia, Cardiomyopathies
Report ID: PMRREP28258
Report Type: Ongoing
Format: PPT*, PDF, EXCEL
Industry: Healthcare
Heart related disorders are mostly inherited from parents to their children. Cardiovascular genomic diagnostics testing helps in detecting these inherited diseases such as cardiac channelopathies and congenital heart diseases. Besides cardiovascular genomic diagnostics can also be helpful for family members who have risks of developing heart problems.
These genetic disorders affect by impairing development of blood vessels which leads to onset of heart diseases. Therefore, cardiovascular genomic diagnostics help in identification of genetic deformities for saving lives.
The technology used for cardiovascular genomic diagnostics testing are NGS (Next generation Sequencing) and Multiplex Ligation-Dependent Probe Amplification (MLPA). These technologies in cardiovascular genomic diagnostics tests read the genetic content of the deceased DNA to identify the changes in its sequence
On the basis of test type |
|
On the basis of disease indication |
|
On the basis of technological platform |
|
On the basis of end users |
|
Geographically, North America is anticipated to be the leading market in the global cardiovascular genomic diagnostics market owing to the increasing number of cardiac diseases. Moreover, the regional market will also rise due to the technological advancement as well as stringent patient care and safety in the region.
The cardiovascular genomic diagnostics markets in the South and East Asia are also anticipated to grow at a significant CAGR due to product expansion offerings by the major global players. In addition, cardiovascular genomic diagnostics is poised to improve the health of population globally by decreasing rate of heart attack and congenital heart diseases. Europe is expected to have the second largest share in the global cardiovascular genomic diagnostics market throughout the forecast period
Some of the Key manufacturers operating in the global cardiovascular genomic diagnostics market include Gnome Diagnostics, Color Genomics, Inc., Creative Diagnostics Thermo Fisher Scientific, Illumina, Inc., Admera Health, Blueprint Genetics Oy., Merck KGaA, MP Biomedicals, LLC., Helix OpCo LLC, CENTOGENE AG, and Oasis Diagnostics Corporation.
These players are adopting sophisticated techniques in the development of cardiovascular genomic diagnostics which will help them for expansion of their product offerings, strengthen geographical presence, and gain strong market share.
We make every effort to deliver the reports as soon as possible. Most reports are delivered within 1 to 2 weeks from order confirmation, though some may take longer depending on the scope.